Stock Research for TGTX

TGTX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

TGTX Stock Chart & Research Data

The TGTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TGTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TGTX Due diligence Resources & Stock Charts

The TGTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TGTX Detailed Price Forecast - CNN Money CNN View TGTX Detailed Summary - Google Finance
Yahoo View TGTX Detailed Summary - Yahoo! Finance Zacks View TGTX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View TGTX Trends & Analysis - Trade-Ideas Barrons View TGTX Major Holders - Barrons
NASDAQ View TGTX Call Transcripts - NASDAQ Seeking View TGTX Breaking News & Analysis - Seeking Alpha
Spotlight View TGTX Annual Report - CompanySpotlight.com OTC Report View TGTX OTC Short Report - OTCShortReport.com
TradeKing View TGTX Fundamentals - TradeKing Charts View TGTX SEC Filings - Bar Chart
WSJ View Historical Prices for TGTX - The WSJ Morningstar View Performance/Total Return for TGTX - Morningstar
MarketWatch View the Analyst Estimates for TGTX - MarketWatch CNBC View the Earnings History for TGTX - CNBC
StockMarketWatch View the TGTX Earnings - StockMarketWatch MacroAxis View TGTX Buy or Sell Recommendations - MacroAxis
Bullish View the TGTX Bullish Patterns - American Bulls Short Pains View TGTX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View TGTX Stock Mentions - StockTwits PennyStocks View TGTX Stock Mentions - PennyStockTweets
Twitter View TGTX Stock Mentions - Twitter Invest Hub View TGTX Investment Forum News - Investor Hub
Yahoo View TGTX Stock Mentions - Yahoo! Message Board Seeking Alpha View TGTX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for TGTX - SECform4.com Insider Cow View Insider Transactions for TGTX - Insider Cow
CNBC View TGTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TGTX - OTC Markets
Yahoo View Insider Transactions for TGTX - Yahoo! Finance NASDAQ View Institutional Holdings for TGTX - NASDAQ


Stock Charts

FinViz View TGTX Stock Insight & Charts - FinViz.com StockCharts View TGTX Investment Charts - StockCharts.com
BarChart View TGTX Stock Overview & Charts - BarChart Trading View View TGTX User Generated Charts - Trading View




Latest Financial News for TGTX


TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
Posted on Tuesday March 12, 2019

TG Therapeutics, Inc. (TGTX), today announced that data from the Phase 2 multicenter trial evaluating ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, to be held May 4 – 10, 2019 in Philadelphia, Pennsylvania. Final data from the core Phase 2 trial has been previously presented, most recently at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting in Dallas, TX. In addition to highlighting the final Phase 2 data, the AAN presentation plans to include data from the open label extension (OLE), a trial made available to any patient who completed the core Phase 2 trial allowing them to continue treatment with ublituximab.


What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
Posted on Monday March 11, 2019

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.


TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference
Posted on Monday March 11, 2019

NEW YORK, March 11, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.


TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
Posted on Friday March 08, 2019

TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated cancers and autoimmune diseases, today announced the successful outcome of meetings held by the independent Data Safety Monitoring Boards (DSMBs) for both the UNITY-CLL trial and for the UNITY-NHL trial. Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, "We are highly encouraged that based on the progression-free survival data accumulated to date, the UNITY-CLL DSMB determined that the study was not futile and supported continuation of the trial as planned.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.